Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 2.4% – What’s Next?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) shares fell 2.4% during mid-day trading on Monday . The stock traded as low as $1.98 and last traded at $2.04. 46,553 shares changed hands during mid-day trading, an increase of 78% from the average session volume of 26,190 shares. The stock had previously closed at $2.09.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research report on Wednesday, January 28th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kiora Pharmaceuticals presently has an average rating of “Hold” and an average price target of $10.00.

Kiora Pharmaceuticals Stock Performance

The company has a market cap of $7.51 million, a price-to-earnings ratio of -0.98 and a beta of -0.80. The company has a 50-day simple moving average of $2.13 and a 200-day simple moving average of $2.26.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC raised its position in Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after acquiring an additional 8,800 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Kiora Pharmaceuticals during the 3rd quarter worth $33,000. Citadel Advisors LLC acquired a new position in shares of Kiora Pharmaceuticals during the 3rd quarter worth $125,000. DRW Securities LLC grew its stake in shares of Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after purchasing an additional 73,417 shares during the period. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Kiora Pharmaceuticals in the 4th quarter valued at about $152,000. Institutional investors and hedge funds own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.